

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)


# Gynecologic Oncology Reports

journal homepage: [www.elsevier.com/locate/gynor](http://www.elsevier.com/locate/gynor)

## Gynecologic Oncology Reports: 2022 and beyond

The past year had been amazing as the world began emerging from Covid but also due to incredible and truly game changing progress in gynecologic cancer treatments with the advent of immunotherapy for front line in endometrial cancer and approvals for antibody drug conjugates for ovarian and cervical cancer to name just a few. At *Gynecologic Oncology Reports*, the year has been spent solidifying the vision and goals outlined last year when our editorial team took over the helm of the journal which serves as one of the official journals for the Society of

and management of side effects of new agents ([Hendershot et al., 2023](#)) or successful use of new agents in rare gynecologic malignancies ([Martel et al., 2023](#)) and get that information out to our readership quickly. As an open access journal, our articles are immediately available online and usage continues to grow; in 2018, the full text usage was about 130,000 and now is over 350,000 annually. This immediate and free access is particularly helpful for those clinicians practicing in LMIC or without easy access to institutional subscriptions to journals.



Gynecologic Oncology. Our 2022 goals were two-fold: (1) to publish and publicize timely and clinically relevant research for clinicians providing care to gynecologic oncology patients and (2) to establish the journal as a resource for students, residents, fellows and attendings to foster and bolster their skills as reviewers and writers in the field. The objective of this editorial is to outline the progress of the journal by focusing on our process, our product and our people and to forecast goals of the future.

The editorial process at *Gynecologic Oncology Reports* continues to grow and improve in number of submissions and speed of decisions. In 2022, there were a record 385 manuscript submissions; the majority remained case reports but original research articles were not far behind and other content continues to expand (e.g. reviews, videos, short communications, SGO journal club distillations) and the journal will receive its first impact factor later this year. Of note, the time required for editorial decisions continued to drop and now stands at a mean of 4.9 weeks from submission to first decision and 9 weeks from submission to online publication which is top tier in journal speed. This incredibly fast turnaround enables results to be disseminated quickly to our society and entire readership and allow immediate utilization to improve patient care. The table of contents for the June 2023 issue highlights the impact of being able to report on both type

In 2022, several initiatives were successfully launched to further our initial goals for the journal as outlined previously to improve our product. First, the inaugural program entitled, “Ridiculously Good Writing: How to Write Like a Pro and Publish Like a Boss” was presented at the 2022 SGO annual meeting and the subsequent article was the top downloaded *Gynecologic Oncology Reports* article in 2022 with over 15,000 downloads—even garnering some interest and trolling on the Facebook group named Reviewer 2 must be Stopped. The journal, in partnership with the SGO’s education committee, also published several of the SGO journal clubs on cervical cancer management (February 2022 issue), maintenance therapy in homologous recombinant proficient ovarian cancer (November 2022) and the ABCs of ADCs (February 2023). *Gynecologic Oncology Reports* will continue to publish case reports, case series, reviews and original manuscripts and is also starting a pipeline of targeted content on seminal topics and evolving clinical care paradigm. We also continue to further grow our social media presence on our Twitter account @GynOncJnls with now almost 2000 followers (from 40 a year ago) which is shared by both SGO journals.

Lastly, it is the people at *Gynecologic Oncology Reports* who make everything possible. I owe a huge thanks to the talented and dedicated

<https://doi.org/10.1016/j.gore.2023.101213>

Available online 24 May 2023

2352-5789/© 2023 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Deputy Editors Drs. Cohn, Fuh, Bakkum-Gamez and Straughn, our global issue special issue editors Drs. Chuang and Mukhopadhyay, our social media editor Dr. Nelson, our [editorial board](#) who review every manuscript, our publisher Ms. Ande Nichols and the entire Elsevier team. We are looking forward to our upcoming team expansion when we will welcome our first class of editorial fellows in July 2023 as we start to mentor the next generation in academic publishing. As we have for the last year, we also continue to invite anyone with an interest in volunteering as a reviewer for *Gynecologic Oncology Reports* to sign up at this [link](#) to have the opportunity to potentially review manuscripts as an additional reviewer and benefit from access to manuscript reviews of experienced editorial board members for immediate feedback. Guest reviewers will also be considered automatically for future openings on the editorial board based on the quality of their reviews. Please never hesitate to reach out to me directly with feedback or ideas in the coming years at the journal inbox ([gynor@elsevier.com](mailto:gynor@elsevier.com)) and I look forward to a

productive 2023 as we strive to improve outcomes for all our patients with gynecologic cancers.

## References

- Hendershot, Andrew, Slabaugh, Mark, Riaz, Kamran M., Moore, Kathleen N., O'Malley, David M., Matulonis, Ursula, Konecny, Gottfried E., 2023. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. *Gynecol. Oncol. Rep.* 47, 101155 <https://doi.org/10.1016/j.gore.2023.101155>.
- Martel, Rachel A., Marsh, Leah, Lai, Tiffany, Rodriguez-Triana, Valentina M., Moatamed, Neda A., Cohen, Joshua, 2023. Use of platinum-based chemotherapy and pembrolizumab to treat squamous cell carcinoma arising in a mature teratoma of the ovary in a pre-menopausal woman with negative response: A case report. *Gynecol. Oncol. Rep.* 47, 101192 <https://doi.org/10.1016/j.gore.2023.101192>.

Susan C. Modesitt, Editor-in-Chief